Why the study?
Does captopril, metoprolol, or hydrochlorothiazide effectively lower blood pressure without causing metabolic deterioration in NIDDM patients with primary hypertension?
Does captopril, metoprolol, or hydrochlorothiazide effectively lower blood pressure without causing metabolic deterioration in NIDDM patients with primary hypertension?
In NIDDM patients with hypertension, captopril and metoprolol effectively lower blood pressure without adverse metabolic effects, whereas hydrochlorothiazide worsens glycemic control and lipid profiles.
Answers are grounded in this paper and cite their sources.
Supports preferring captopril or metoprolol over hydrochlorothiazide in hypertensive NIDDM; confirms metabolic neutrality of the former in this population.
The antihypertensive effect of captopril, metoprolol, and hydrochlorothiazide was compared in 23 non-insulin-dependent (NIDDM) diabetic patients less than or equal to 75 years of age, with borderline to moderate primary hypertension. In a double blind, placebo-controlled cross-over trial the patients were treated with 25 to 50 mg captopril, 50 to 100 mg metoprolol, 12.5 to 25 mg hydrochlorothiazide, and placebo, each given twice daily for 8 weeks. Antidiabetic treatment remained unchanged during the study. After receiving placebo for a 4 week run-in period, arterial blood pressure was 168/101 +/- 93/10 (mean +/- SEM) mm Hg. Diastolic blood pressure was lowered significantly during all active treatment periods compared to the placebo value of 97 +/- 2 mm Hg: captopril, 92 +/- 1 mm Hg; metoprolol, 90 +/- 1 mm Hg; hydrochlorothiazide, 91 +/- 1 mm Hg. Metabolic variables were not significantly altered by captopril and metoprolol, while hydrochlorothiazide treatment increased hemoglobin A1c from 7.5 +/- 0.3 to 8.2 +/- 0.4% (P less than .001), decreased high-density lipoprotein-cholesterol from 1.19 +/- 0.08 to 1.10 +/- 0.06 mmol/L (P less than .05). Glomerular filtration rate, urinary albumin excretion, orthostatic blood pressure response, and digital systolic blood pressure in the lower limb remained unchanged during the active treatment periods. The frequency of subjective adverse effects was acceptable during active treatment and not significantly different compared to placebo. We conclude that antihypertensive treatment for 8 weeks with captopril or metoprolol in NIDDM patients is well-tolerated and causes no deterioration in metabolic control and kidney function, while hydrochlorothiazide causes a slight deterioration in glycemic control and lipid profile.
No takes yet. Share an insight, caveat, or question.
Gall et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: